| Literature DB >> 33490663 |
Kuniaki Yabe1,2, Yasuko Yamamoto1, Masao Takemura3, Takeshi Hara4, Hisashi Tsurumi4, Ginette Serrero5,6, Toshitaka Nabeshima3,7, Kuniaki Saito1,3,7,8.
Abstract
Progranulin is an autocrine growth factor that promotes proliferation, migration, invasion, and chemoresistance of various cancer cells. These mechanisms mainly depend on the protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway. Recent studies have shown that patients with hematopoietic cancer have elevated serum progranulin levels. Thus, the current study aimed to investigate the role of progranulin in hematopoietic cancer cells and how it modulates their proliferation. Both knockdown of progranulin and progranulin neutralizing antibody treatment inhibited proliferation in several human hematopoietic cancer cell lines. Moreover, progranulin depletion not only decreases the phosphorylation level of the Akt/mTOR pathway but also, surprisingly, increases the expression of transforming growth factor-beta (TGF-β) and phosphorylation of mothers against decapentaplegic homolog 2 (SMAD2) in Kasumi-1 cell. Furthermore, LY2109761, an inhibitor of TGF-β receptor type I/II kinase, and TGF-β neutralizing antibody blocked the inhibition of proliferation induced by progranulin depletion. These data provide new insights that progranulin alters cell proliferation via the TGF-β axis and progranulin could be a new therapeutic target for hematopoietic cancers.Entities:
Keywords: Hematologic neoplasms; Mechanistic target of rapamycin complex 1; Progranulin; Transforming growth factor beta
Year: 2021 PMID: 33490663 PMCID: PMC7809376 DOI: 10.1016/j.heliyon.2020.e05849
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440